LOGIN  |  REGISTER
Cue Biopharma
Compass Therapeutics

Novavax to Participate in BofA Securities 2025 Health Care Conference

May 07, 2025 | Last Trade: US$7.84 0.21 2.75

GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Conference Details:

 

Fireside Chat

 

Date:

Wednesday, May 14, 2025

Time:

3:00 – 3:30 p.m. Pacific Time (PT)

Location:

Las Vegas, NV

  

Conference

 

Event:

Investor Meetings

Date:

Wednesday, May 14, 2025

     

A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, which includes protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information. 

Contacts: 

Investors 
Luis Sanay, CFA
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Giovanna Chandler
202-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.

 
Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page